Muthukumar R: What if One Blood Test Could Tell Doctors Much More Than it Does Today?
Muthukumar R, Founder & CEO of Azaygen India, shared a post on LinkedIn.
“What if one blood test could tell doctors much more than it does today?
That’s the kind of conversation we recently had at the Hematology Department of Christian Medical College (CMC) Vellore Ranipet Campus, while introducing the Randox Evidence MultiStat.
Under the guidance of Dr. Vikram Mathews , the discussion centered on how modern diagnostics are shifting toward seeing the bigger clinical picture especially in understanding Inflammation and immune response.
Instead of running multiple separate tests, the MultiStat can Analyze 9 key biomarkers in a single run. This allows clinicians to understand what’s happening inside the body faster.
And more clearly, whether the concern is infection, clotting complications ,or hematologic disorders.
Markers such as IL-6, TNF-α, Interferon-Gamma, and IL-2 play a critical role in immune regulation and inflammatory pathways.
The ability to obtain insights on these markers in around 60 minutes is especially valuable when managing critically ill patients.
What stood out most was how easily the system fits into real lab workflows compact, efficient, and built for high-volume environments where time truly matters.
More than a technology introduction,it was a meaningful exchange of ideas on where diagnostics is heading. And how precision medicine is becoming increasingly practical.Progress like this happens through collaboration.
And a willingness to rethink how we interpret the body’s signals.”
Stay updated with Hemostasis Today.
-
Sep 20, 2026, 03:22The Voices of People Living With Bleeding Disorders – EHC
-
Sep 20, 2026, 01:18Sebastian Mafeld: Has 2026 Changed How We Treat Pulmonary Embolism?
-
Sep 20, 2026, 01:16Pall T. Onundarson: DOACs – Monitoring, Tailoring Dose and Identifying Problems
-
Sep 20, 2026, 01:15Thierry Fumeaux: From Efficacy to Effectiveness – The Value of Real-World Evidence
-
Sep 20, 2026, 01:14Said El Shamieh: VEGFA Genetic Variants and Bleeding Risk During Warfarin Therapy
-
Sep 20, 2026, 01:04Omar Danoun: Levetiracetam May Increase Thromboembolic Risk With DOACs
-
Sep 20, 2026, 01:02Mohamed Abo-Aly: Which Antiseizure Medication is Safest for Patients on DOACs?
-
Sep 20, 2026, 00:58Hamza Rafiq: How Does a Deep Vein Thrombosis Become a PE?
-
Sep 20, 2026, 00:50A Shared Platelet Factor 4–Targeted Immune Mechanism in Adenovirus Infection – NEJM